Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission
Abstract
Patients with acute myeloid leukemia (AML) without complete remission (CR) or in first relapse (Rel1) can have extended leukemia control and survival after allogeneic hematopoietic cell transplantation (HCT). For patients in Rel1 or primary induction failure (PIF), transplantation versus treatment to achieve a second CR (CR2) and subsequent HCT might yield similar outcomes, but available comparative data are scarce.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 24, 2017
- Source ID
- 10.1002/cncr.30536
Entities
People
- Andrew Rezvani
- Brenda Sandmaier
- Daniel J Weisdorf
- Hanna J Khoury
- Heather R. Millard
- Keith Stockerl‐goldstein
- Marco Mielcarek
- Marcos de Lima
- Mary Eapen
- Mary M. Horowitz
- Mei Jie Zhang
- Parvinder S. Hyare
- Richard Champlin
- Vincent Ho
- Wael Saber
Organizations
- Alexion Pharmaceuticals
- Astellas Pharma (United States)
- AstraZeneca
- AstraZeneca (United States)
- Barnes-Jewish Hospital
- Celgene
- Chiron Corporation
- Elevance Health, Inc.
- Emory University
- Fred Hutchinson Cancer Center
- Genzyme
- Gilead Sciences
- Health Research
- Health Resources and Services Administration
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- Office of Naval Research
- Onyx Pharmaceuticals
- Otsuka (United States)
- Patient-Centered Outcomes Research Institute
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Seagen
- Seattle Cancer Care Alliance
- St. Baldrick's Foundation
- Sunesis Pharmaceuticals
- UH Cleveland Medical Center
- University of Minnesota
- University of Texas at Austin
- University of Washington